UCB PHARMA AS

0161 OSLO

Finances

Share Ownership

Return on Equity

18,41 %

Current Ratio

1,29

Debt-to-Equity Ratio

Key figures (NOK)	2022	2021	2020	2019
Revenue	230 808 000	250 217 000	256 923 000	278 127 000
Net Income	5 226 000	5 916 000	6 951 000	7 519 000
Total Assets	126 234 000	135 197 000	144 594 000	133 832 000
Total Equity	28 380 000	28 325 000	22 424 000	15 394 000

Income (NOK)	2022	2021	2020	2019
Revenue	230 808 000	250 217 000	256 923 000	278 127 000
Expenditure	223 056 000	241 908 000	247 542 000	267 358 000
Operating Profit	7 751 000	8 309 000	9 381 000	10 769 000
Financial Income	1 003 000	728 000	864 000	433 000
Financial Costs	1 811 000	1 168 000	1 307 000	1 511 000
Financial Balance	−808 000	−440 000	−443 000	−1 078 000
Earnings Before Tax	6 944 000	7 869 000	8 938 000	9 691 000
Tax	1 717 000	1 953 000	1 987 000	2 173 000
Net Income	5 226 000	5 916 000	6 951 000	7 519 000

Balance (NOK)	2022	2021	2020	2019
Total Fixed Assets	141 000	93 000	43 000	86 000
Total Current Assets	126 094 000	135 103 000	144 551 000	133 746 000
Total Assets	126 234 000	135 197 000	144 594 000	133 832 000
Total Retained Equity	23 537 000	23 611 000	17 695 000	10 744 000
Total Equity	28 380 000	28 325 000	22 424 000	15 394 000
Total Long-Term Debt	0	0	0	0
Total Current Debt	97 854 000	106 871 000	122 170 000	118 438 000
Total Equity and Debt	126 234 000	135 197 000	144 594 000	133 832 000

Cash flow (NOK)	2022	2021	2020	2019
Sales Income	230 808 000	250 217 000	256 923 000	278 127 000
Other Income	0	0	0	0
Revenue	230 808 000	250 217 000	256 923 000	278 127 000
Cost of Goods Sold	158 060 000	193 497 000	204 001 000	237 347 000
Salary Costs	13 947 000	12 548 000	7 706 000	4 441 000
Depreciation	0	0	0	0
Impairment	0	0	0	0
Expenditure	223 056 000	241 908 000	247 542 000	267 358 000
Operating Profit	7 751 000	8 309 000	9 381 000	10 769 000
Financial Income	1 003 000	728 000	864 000	433 000
Financial Costs	1 811 000	1 168 000	1 307 000	1 511 000
Financial Balance	−808 000	−440 000	−443 000	−1 078 000
Dividends	5 300 000	0	0	0
Net Income	5 226 000	5 916 000	6 951 000	7 519 000

Balance details (NOK)	2022	2021	2020	2019
Goodwill	0	0	0	0
Total Intangible Assets	141 000	93 000	43 000	86 000
Real Eastate	0	0	0	0
Machinery and Plant Facilities	0	0	0	0
Fixtures	0	0	0	0
Total Tangible Assets	0	0	0	0
Total Fiancial Fixed Assets	0	0	0	0
Total Fixed Assets	141 000	93 000	43 000	86 000
Stock	44 608 000	57 882 000	65 092 000	58 063 000
Total Investments	0	0	0	0
Cash, Bank	9 873 000	9 927 000	9 539 000	8 460 000
Total Current Assets	126 094 000	135 103 000	144 551 000	133 746 000
Total Assets	126 234 000	135 197 000	144 594 000	133 832 000
Total Equity	28 380 000	28 325 000	22 424 000	15 394 000
Short-Term Group Debt	0	0	0	0
Total Long-Term Debt	0	0	0	0
Creditors	43 844 000	39 505 000	47 066 000	36 168 000
Unpaid Taxes	9 140 000	9 648 000	10 599 000	11 856 000
Dividends	5 300 000	0	0	0
Other Current Debt	37 805 000	55 729 000	62 561 000	68 336 000
Total Current Debt	97 854 000	106 871 000	122 170 000	118 438 000
Total Equity and Debt	126 234 000	135 197 000	144 594 000	133 832 000

Financial indicators	2022	2021	2020	2019
Return on Equity	18,41 %	20,89 %	31 %	48,84 %
Debt-to-Equity Ratio	0	0	0	0
Operating Profit Margin	3,36 %	3,32 %	3,65 %	3,87 %
Current Ratio	1,29	1,26	1,18	1,13
Quick Ratio	2,37	2,76	2,53	2,22
Equity Ratio	0,22	0,21	0,16	0,12
Gross Profit Margin	31,52 %	22,67 %	20,6 %	14,66 %